Physician profile
John M Waples
NPI 1790765337
$18,610.54
in general payments reported to CMS, 2019-2025
66 companies · $8,482 in 2025
The $8,482 reported for 2025 was more than what 79% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,397 · 2020: $1,668 · 2021: $621 · 2022: $1,188 · 2023: $2,109 · 2024: $2,145 · 2025: $8,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,764 · Consulting Fee: $5,200 · Grant: $501 · Education: $152 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,763.82 |
| Consulting Fee | $5,200.00 |
| Grant | $500.50 |
| Education | $151.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $3,927.17 | 2019-2025 | |
| Pfizer INC. | $2,051.78 | 2019-2025 | |
| Janssen Biotech, INC. | $1,394.67 | 2019-2025 | Tecvayli, Darzalex, Rybrevant |
| Seagen INC. | $816.35 | 2020-2023 | Tukysa, Padcev, Adcetris |
| Abbvie INC. | $778.68 | 2019-2025 | Epkinly, Venclexta, Creon |
| Amgen INC. | $733.59 | 2019-2024 | Vectibix, Blincyto, Lumakras |
| Genzyme Corporation | $640.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $603.72 | 2019-2025 | Imfinzi, Calquence |
| Novartis Pharmaceuticals Corporation | $574.49 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $482.89 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Welch Allyn | $432.31 | 2021 | |
| Eisai INC. | $378.96 | 2019-2024 | |
| Glaxosmithkline, LLC. | $361.93 | 2022-2025 | Ojjaara, Blenrep, Jemperli |
| Beigene USA, INC. | $350.09 | 2022-2025 | Brukinsa, Tevimbra |
| Karyopharm Therapeutics INC. | $323.27 | 2020-2024 | Xpovio |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Waples listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.